直肠牵开器对宫颈癌近距离放疗剂量参数、不良事件及临床结局的影响
这项回顾性单中心研究纳入148例接受腔内近距离放疗的宫颈癌患者,比较使用与未使用直肠牵开器的剂量学、体积参数、不良事件和生存结局。结果显示直肠牵开器使用与直肠D2cc降低(65.70 Gy vs 60.79 Gy,p=0.002)及≥2级阴道不良事件减少(32.8% vs 56.7%,p=0.004)相关,但膀胱D2cc升高(75.59 Gy vs 80.08 Gy,p<0.001),靶区覆盖无差异。
要点
- 直肠牵开器使用与直肠D2cc降低相关,但膀胱D2cc升高。
- 使用直肠牵开器组≥2级阴道不良事件发生率更低。
- 直肠牵开器使用未影响靶区覆盖,但放置非随机化。
核心结论
- 直肠牵开器使用与直肠剂量 sparing 和≥2级阴道不良事件 odds 降低相关,且不损害靶区覆盖。
- 但该发现需谨慎解读,因为直肠牵开器放置非随机化且受施源器兼容性影响。
研究设计与样本
- 回顾性三级中心研究,纳入2020年6月至2025年6月间接受腔内近距离放疗的148例宫颈癌患者。
- 比较使用与未使用直肠牵开器患者的剂量学、体积、不良事件和生存结局,不良事件按RTOG标准分级。
主要发现
- 直肠牵开器使用58例(39.2%),两组基线人口学特征和肿瘤大小可比,但施源器类型分布不同。
- 直肠牵开器组直肠D2cc更低(60.79 Gy vs 65.70 Gy,p=0.002),膀胱D2cc更高(80.08 Gy vs 75.59 Gy,p<0.001)。
- 处方EQD2、HR-CTV覆盖、乙状结肠D2cc和体积参数两组相似。
- 直肠牵开器组≥2级阴道不良事件更少(32.8% vs 56.7%,p=0.004),≥2级直肠(p=0.380)或泌尿(p=0.083)不良事件无显著差异。
- ROC分析显示首次分次体积参数对≥2级不良事件的判别能力有限(AUC范围0.417-0.613)。
关键数值与推荐
- 多因素分析显示直肠牵开器使用与≥2级阴道不良事件 odds 降低相关(OR 0.29;95% CI,0.13-0.63;p=0.002)。
- 累积剂量参数采用EQD2计算。
临床怎么用
- 在宫颈癌腔内近距离放疗中,可考虑使用直肠牵开器以降低直肠D2cc和≥2级阴道不良事件风险,但需注意膀胱D2cc可能升高。
- 施源器兼容性可能影响直肠牵开器的使用,临床决策需个体化。
局限性
- 回顾性设计,直肠牵开器放置非随机化,且受施源器兼容性影响,可能存在混杂偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: We assessed whether rectal retractor use was associated with dose parameters, organ volumes, treatment-related adverse events, and oncological outcomes in patients who underwent cervical cancer brachytherapy. MATERIALS AND METHODS: This retrospective study included 148 patients treated with intracavitary brachytherapy between June 2020 and June 2025. Patients treated with and without a rectal retractor were compared regarding dosimetric, volumetric, adverse event, and survival outcomes. Adverse events were graded via RTOG criteria. Cumulative dose parameters were calculated using EQD2. ROC analysis and multivariable logistic regression were performed to evaluate factors associated with grade ≥ 2 adverse events. RESULTS: Rectal retractor use occurred in 58 patients (39.2%). Baseline demographic characteristics and tumour size were comparable between groups, although rectal retractor use differed according to applicator type. Rectal retractor use was associated with lower rectal D2cc (no retractor vs. retractor: 65.70 Gy vs. 60.79 Gy, p = 0.002) but higher bladder D2cc (no retractor vs. retractor: 75.59 Gy vs. 80.08 Gy, p < 0.001) values. Prescribed EQD2, HR-CTV coverage, sigmoid D2cc, and volumetric parameters were similar. Grade ≥ 2 vaginal adverse events were less frequent in the retractor group than in the no-retractor group (32.8% vs. 56.7%, p = 0.004). No significant difference was observed in grade ≥ 2 rectal (p = 0.380) or urinary adverse events (p = 0.083). ROC analysis showed that first-fraction volumetric parameters had limited discriminatory ability for grade ≥ 2 adverse events (AUC range: 0.417-0.613). In multivariable analysis, rectal retractor use was associated with lower odds of grade ≥ 2 vaginal adverse events (OR 0.29; 95% CI, 0.13-0.63; p = 0.002). CONCLUSIONS: Rectal retractor use was associated with rectal dose sparing and lower odds of grade ≥ 2 vaginal adverse events without compromising target coverage. However, this finding should be interpreted cautiously because rectal retractor placement was not randomised and was influenced by applicator compatibility.
引用
- Hazırbulan A, Kızıltan HŞ, Çepni K, et al. Effects of rectal retractor use on dosimetric parameters, treatment-related adverse events, and clinical outcomes of cervical cancer brachytherapy: A retrospective tertiary-centre study. Clin Transl Radiat Oncol. 2026. PMID: 42871204. doi:10.1016/j.ctro.2026.101302
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。